Published in Prim Care Companion CNS Disord on January 01, 2011
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder | NCT01309542
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D (2016) 0.75
Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial. Prim Care Companion CNS Disord (2015) 0.75
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet (2007) 15.96
Global burden of depressive disorders in the year 2000. Br J Psychiatry (2004) 9.25
The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry (2003) 7.19
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (2003) 5.75
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry (2000) 5.38
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry (1998) 3.27
Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry (1998) 1.63
Social functioning in depression: a review. J Clin Psychiatry (2000) 1.62
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther (1997) 1.54
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin (2008) 1.41
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther (2006) 1.41
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol (2008) 1.36
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry (2001) 1.31
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry (2007) 1.29
Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry (2004) 1.26
Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry (2003) 1.25
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol (2007) 1.18
Predictors of self-reported antidepressant adherence. Behav Med (2007) 1.16
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord (2002) 1.15
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol (2008) 1.14
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry (2007) 1.12
Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry (2004) 1.02
Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord (1984) 1.00
An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr (2009) 1.00
Depressive disorders in primary care: recurrent, chronic, and co-morbid. Psychol Med (2005) 0.97
Antidepressants and sexual dysfunction. Acta Psychiatr Scand (2006) 0.96
Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychol Med (2009) 0.96
Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry (2000) 0.95
A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin (2007) 0.95
Long term outcome of primary care depression. J Affect Disord (2009) 0.91
Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol (1994) 0.90
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos (2008) 0.88
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol (2010) 0.88
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr (2009) 0.86
Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull (2009) 0.84
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety (2008) 0.83
Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? Psychother Psychosom (1998) 0.83
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr (2009) 0.83
A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol (1997) 0.82
Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol (1996) 0.82
The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol (2008) 0.80
Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry (2010) 0.80
A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry (2008) 0.78
Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand (1997) 0.78
Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol (2001) 0.77
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol (2007) 1.18
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol (2008) 1.14
Adaptive designs for dose-finding studies based on sigmoid Emax model. J Biopharm Stat (2007) 0.89
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol (2010) 0.88
Circadian organization in a diurnal rodent, Arvicanthis ansorgei Thomas 1910: chronotypes, responses to constant lighting conditions, and photoperiodic changes. J Biol Rhythms (2002) 0.85
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr (2009) 0.83
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol (2005) 0.81
Entrainment of locomotor activity rhythm in pinealectomized adult Syrian hamsters by daily melatonin infusion. Behav Brain Res (2002) 0.79
High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr (2012) 0.78
Entrainment of circadian activity rhythms in rats to melatonin administered at T cycles different from 24 hours. Neurosignals (2002) 0.77
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin (2010) 0.77
Environmental control and adrenergic regulation of pineal activity in the diurnal tropical rodent, Arvicanthis ansorgei. J Pineal Res (2005) 0.76
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study. Innov Clin Neurosci (2011) 0.75
Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. J Clin Psychiatry (2004) 0.75